Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between ...

Study cohort began collecting data on newborns through adulthood, and may offer objective clues on asthma and COPD disease ...

Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...

A class action lawsuit was filed against Regeneron Pharmaceuticals, Inc. (REGN) by Levi & Korsinsky on January 7, 2025. The ...

Regeneron last year won European Commission approval of odronextamab as Ordspono for relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma after two or more lines of systemic ...

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...

The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results ...

Regeneron Pharmaceuticals (NASDAQ:REGN) said on Wednesday that the U.S. FDA has accepted its resubmitted Biologics License ...

MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA," the "Company"), a clinical-stage biopharmaceutical company ...

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...